![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
New HCV Protease: Preclinical Characteristics and Microdosing Pharmacokinetics in Healthy Volunteers Support a Low-Dose, Once-Daily Dosing Regimen of the HCV NS3/4a Protease Inhibitor ITMN-8187
|
|
|
Ravi Rajagopalan
InterMune Inc., Brisbane, CA
Reported by Jules Levin
The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
Boston, MA June 23-24, 2010
![](../images/062810/062810-4/image002.gif)
![](../images/062810/062810-4/image004.gif)
![](../images/062810/062810-4/image006.gif)
![](../images/062810/062810-4/image008.gif)
![](../images/062810/062810-4/image010.gif)
![](../images/062810/062810-4/image012.gif)
![](../images/062810/062810-4/image014.gif)
![](../images/062810/062810-4/image016.gif)
![](../images/062810/062810-4/image018.gif)
![](../images/062810/062810-4/image020.gif)
![](../images/062810/062810-4/image022.gif)
![](../images/062810/062810-4/image024.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|